Sunil Rajanikant Mehta
Direktor/Vorstandsmitglied bei Emcure Pharmaceuticals Ltd.
Vermögen: 111 $ am 30.09.2021
Profil
Sunil Rajanikant Mehta is currently the Executive Director & Executive Director-Projects at Emcure Pharmaceuticals Ltd.
and Director at Gennova Biopharmaceuticals Ltd.
He completed his undergraduate degree from the University of Pune and his MBA from the Institute of Management, Development & Research.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
Emcure Pharmaceuticals Ltd.
 Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. 6,13% | 18.08.2021 | 11 085 012 ( 6,13% ) | 111 $ | 30.09.2021 |
Aktive Positionen von Sunil Rajanikant Mehta
| Unternehmen | Position | Beginn |
|---|---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Direktor/Vorstandsmitglied | 05.06.2013 |
Gennova Biopharmaceuticals Ltd.
 Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Gennova Biopharmaceuticals Ltd. specializes in biotechnology research for biosmiliars, vaccines, and mAbs using recombinant DNA technology. The company was founded on June 19, 2001 and is headquartered in Pune, India. | Direktor/Vorstandsmitglied | 19.06.2001 |
Ausbildung von Sunil Rajanikant Mehta
| University of Pune | Undergraduate Degree |
| Institute of Management, Development & Research | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Health Technology |
Gennova Biopharmaceuticals Ltd.
Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Gennova Biopharmaceuticals Ltd. specializes in biotechnology research for biosmiliars, vaccines, and mAbs using recombinant DNA technology. The company was founded on June 19, 2001 and is headquartered in Pune, India. | Commercial Services |